Resources

Join Winston Taylor and Raymond James on 23rd September 2026 in London, as we bring together leaders who've built, scaled, and exited growth-stage businesses. A sharp, practical discussion on the routes to growth, liquidity, and exit.

UK Life Sciences Innovation Signals Report (H1 2026) explores how effectively the UK is converting scientific innovation into commercial growth, healthcare adoption, and patient impact. The report assesses three critical areas: Capital, Capability, and Conversion, revealing that while investment remains strong (£2.83bn raised in H1 2026) and research capabilities continue to improve, the sector's biggest challenge is turning innovation into widespread adoption across healthcare systems and markets. Key findings show that funding is increasingly concentrated in a small number of high-conviction companies, regulatory and clinical trial processes are becoming more efficient, and NHS adoption of new innovations is improving but remains inconsistent. The report provides valuable insights for founders, CFOs, investors, and industry leaders looking to understand the trends, opportunities, and challenges shaping the future of UK life sciences.

Pioneer Group and Oxford Properties have announced that Syncona Investment Management Ltd (SIML), a leading life science investment manager, is moving into Victoria House, a leading hub for life sciences in London.

How recent British Business Bank commitments and BIA member milestones are keeping UK life sciences momentum strong

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.

Chris Molloy on mRNA cancer vaccine reaching Phase 3 milestone, Scancell MHRA authorisation, microbiome-based medicinal products, MHRA voucher scheme for SMEs, Scotland and data driver projects

Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease

The advantages to building a business in the UK's biotech clusters

Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement

Find out more about a free, independent review of R&D tax claims for BIA members.

Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology.

Moa Technology announces a £22.2 million Series C financing round

Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.

From first-in-class approvals to billion-dollar deals, Q2 2026 signals a new era for antibody innovation

Chris Molloy on the Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion, including a record £2.05 billion in venture capital.

The British Business Bank has invested in Draig Therapeutics as part of its $65 million Series B financing round.